SERD for ET Resistance

CE / CME

Steps Toward Precision Oncology: Role of SERD in Attacking Endocrine Resistance in HR+/HER2- Breast Cancer

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

ABIM MOC: maximum of 0.75 Medical Knowledge MOC point

Released: May 30, 2024

Expiration: May 29, 2025

Aditya Bardia
Aditya Bardia, MD, MPH, FASCO

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

For patients with breast cancer with disease progression on CDK4/6i + ET, which mutation would make them candidates for an approved oral SERD?